S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:MYGNMyriad Genetics Stock Price, Forecast & News

$13.07
+0.64 (+5.15 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.30
Now: $13.07
$13.12
50-Day Range
$10.69
MA: $11.77
$12.48
52-Week Range
$9.24
Now: $13.07
$35.29
Volume881,400 shs
Average Volume1.10 million shs
Market Capitalization$974.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
Myriad Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.8Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$851.10 million
Cash Flow$2.49 per share
Book Value$14.84 per share

Profitability

Net Income$4.60 million

Miscellaneous

Employees2,600
Market Cap$974.43 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$13.07
+0.64 (+5.15 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by Coronavirus?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MYGN stock has decreased by 6.8% and is now trading at $13.07.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Myriad Genetics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Myriad Genetics
.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Myriad Genetics
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Tuesday, May, 5th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.10. The business earned $164 million during the quarter, compared to analysts' expectations of $167.38 million. Myriad Genetics had a negative net margin of 19.49% and a positive return on equity of 1.95%. The business's quarterly revenue was down 24.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.46 EPS.
View Myriad Genetics' earnings history
.

What price target have analysts set for MYGN?

8 brokers have issued 12 month price targets for Myriad Genetics' shares. Their forecasts range from $10.00 to $36.00. On average, they expect Myriad Genetics' share price to reach $21.25 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price.
View analysts' price targets for Myriad Genetics
.

Has Myriad Genetics been receiving favorable news coverage?

Press coverage about MYGN stock has been trending extremely negative this week, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myriad Genetics earned a coverage optimism score of -4.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Myriad Genetics
.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 8,910,000 shares, an increase of 20.2% from the May 31st total of 7,410,000 shares. Based on an average trading volume of 1,190,000 shares, the days-to-cover ratio is presently 7.5 days. Currently, 12.3% of the company's shares are sold short.
View Myriad Genetics' Short Interest
.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (1.83%), Goldman Sachs Group Inc. (1.53%), Bank of New York Mellon Corp (1.27%), New York State Common Retirement Fund (1.15%), Principal Financial Group Inc. (0.85%) and CWM LLC (0.39%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Gary A King, John T Henderson, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics
.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, New York State Common Retirement Fund, UBS Group AG, First Quadrant L P CA, Texas Permanent School Fund, State of Tennessee Treasury Department, SG Americas Securities LLC, and New York State Teachers Retirement System.
View insider buying and selling activity for Myriad Genetics
.

Which major investors are buying Myriad Genetics stock?

MYGN stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Goldman Sachs Group Inc., Marshall Wace LLP, Duality Advisers LP, Nordea Investment Management AB, Marshall Wace North America L.P., Bank of New York Mellon Corp, and Principal Financial Group Inc.. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics
.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $13.07.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $974.43 million and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.